1stOncology™: Cancer Intelligence Service – Page 413 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Lantheus to Present at March 2026 Investor Conferences

On February 24, 2026 Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver better patient outcomes, reported Mary Anne Heino, Executive Chairperson and Chief Executive Officer, will present at the following investor conferences.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

TD Cowen 46th Annual Health Care Conference
March 3, 2026 at 11:10 a.m. ET

Leerink Global Healthcare Conference
March 10, 2026 at 8:00 a.m. ET
To access the live webcast of the presentations, please visit the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentation.

(Press release, Lantheus, FEB 24, 2026, View Source [SID1234662966])

MiraDx Launches New Genetic Test Expanding Radiation Therapy Risk Assessment for Prostate Cancer Patients

On February 24, 2026 MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, reported the U.S. commercial launch of PROSTOX Standard, a new, clinically validated genetic test that expands access to personalized radiation therapy for patients with localized prostate cancer. The test identifies those at increased risk of developing long-term urinary side effects following conventionally fractionated or moderately hypofractionated radiation therapy (CFRT or MHFRT), and complements the company’s existing PROSTOX Ultra offering, for patients being considered for stereotactic body radiation therapy (SBRT). By offering both tests, MiraDx is expanding access to toxicity risk assessment testing to a broader group of prostate cancer patients at risk for genitourinary (GU) toxicity following external beam radiation therapy (EBRT).

While EBRT is an effective and widely used treatment for localized prostate cancer, more than 20% of patients treated with radiation therapy experience persistent urinary side effects, referred to as late GU toxicity.1 PROSTOX tests help predict late-onset genitourinary (GU) toxicity—side effects such as urinary urgency, leakage, or discomfort—that can appear months or years after radiation treatment and significantly impact quality of life.

Localized prostate cancer has an excellent prognosis with a five-year survival rate of over 99%.2 Although SBRT, CFRT, and MHFRT have similar efficacy in this population, individual responses to each treatment method can vary due to a patient’s genetics. Until now, clinicians have lacked a biology-driven tool to identify which patients are most at risk for GU toxicity from each EBRT method. PROSTOX tests address this gap by analyzing inherited genetic variants in microRNAs and their pathways that influence how individual patients tolerate radiation. Using a simple cheek swab, PROSTOX delivers actionable results in 5-7 days, enabling physicians and patients to make more personalized radiation treatment decisions based upon each patient’s individual side effect risk profile.

"PROSTOX tests bring precision medicine to radiation oncology by shifting the focus from the tumor alone to determining the most effective treatment approach for each patient based upon their unique biology and resulting treatment risks," said Melissa C. Stoppler, MD, Executive Vice President of Medical Affairs at MiraDx. "Having information about which type of radiation each patient will tolerate best allows clinicians to better tailor radiation treatments to patients, helping them avoid future long-term side effects."

Each PROSTOX test evaluates genetic risk across a different radiation therapy regimen. A result that a patient is at high risk with PROSTOX Standard does not imply a high-risk result for PROSTOX Ultra, and vice versa. In rare cases (less than 2% of patients), PROSTOX tests will identify that a patient has a high risk for late GU side effects with both SBRT and CFRT/MHFRT. For these patients, other interventions may be available.

"Being diagnosed with prostate cancer is life altering and comes with many decisions and so much uncertainty," said Ron Stewart, a patient who received PROSTOX testing. "The PROSTOX test helped me feel more confident about my treatment plan and more optimistic that my cancer treatment would not hamper my quality of life down the road."

PROSTOX Standard and PROSTOX Ultra are commercially available in the U.S. and performed at MiraDx’s CLIA-certified and CAP-accredited molecular diagnostics laboratory in Los Angeles, Calif. Coverage may vary by insurance plan. MiraDx offers a financial assistance program to help ensure patient access to PROSTOX tests.

About PROSTOX Tests

PROSTOX tests are clinically validated diagnostic tests used to predict genitourinary toxicity following external beam radiation therapy (EBRT). The tests analyze inherited genetic variants in microRNAs and their pathways that influence how individual patients tolerate radiation, delivering actionable insights to enable clinicians to make informed therapeutic choices with their families. The PROSTOX Standard test is designed to predict toxicity following CFRT (37-45 fractions over 7-9 weeks) or MHFRT (20-28 fractions over 4-5 weeks). The PROSTOX Ultra test is designed to predict toxicity following SBRT (5–7 fractions over approximately 10 days).

(Press release, MiraDx, FEB 24, 2026, View Source [SID1234662956])

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

On February 14, 2026 Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, reported results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Data was recently presented in an oral plenary at the 2026 MHNCS.

Approximately 73K patients are diagnosed with head and neck cancer in the U.S. annually. The current standard of care for R/M HNSCC patients, based on the registrational KEYNOTE-048 trial, is immune checkpoint inhibition (ICI) either alone, or combined with chemotherapy; however, these regimens are suboptimal with efficacy and toxicity concerns. To help address these issues, SINERGY (NCT05420948) investigated whether personalized circulating tumor DNA (ctDNA) monitoring with Signatera can provide an early signal of treatment efficacy, enabling adaptive escalation or de-escalation of chemotherapy without reducing therapeutic benefit.

In the trial, 27 patients received initial treatment of either immunotherapy alone or in combination with chemotherapy. Based on Signatera ctDNA dynamics during treatment (ctDNA levels rising or falling), chemotherapy was either escalated or de-escalated.

The study met its primary endpoint (objective response rate), with the following key highlights:

74% of patients (20/27) were de-escalated from chemo-immunotherapy to immunotherapy alone, resulting in a median of 2 chemotherapy cycles across the full cohort, a substantial two-thirds reduction from the current standard of care (6 cycles).
Objective response rate (ORR) was strong at 63% (17/27; 95% CI: 42.4–80.6), comparing favorably to the 36% and 19% ORRs from KEYNOTE-048 patients receiving ICI with and without chemotherapy, respectively.
Severe toxicity of grade ≥3 was 48.1% (13/27), substantially lower than the 85% and 55% from KEYNOTE-048 patients receiving ICI with and without chemotherapy, respectively.
"The SINERGY trial is unique in that it adapted chemo-immunotherapy treatment guided by ctDNA dynamics. The trial demonstrated a promising response rate and survival, with roughly three-quarters of patients experiencing treatment de-escalation guided by ctDNA dynamics," said Ari J. Rosenberg, M.D., associate professor of medicine at the University of Chicago and presenting author of the study. "This led to a reduction in the number of chemotherapy cycles along with lower rates of high-grade toxicity compared with historical controls. With these results, there is great potential for ctDNA dynamics to optimize treatment in R/M HNSCC."

"This trial was designed to address an urgent need for treatment personalization that mitigates unnecessary toxicity while improving survival for patients with recurrent or metastatic head and neck cancer," said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera. "We saw remarkable results that Signatera can inform therapeutic decision-making in real-time for this aggressive and difficult-to-treat cancer, laying the groundwork for changes in the standard of care."

(Press release, Natera, FEB 24, 2026, View Source [SID1234662955])

Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications

On February 24, 2026 Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) reported that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx Spatial Molecular Imager (SMI). CosMx SMI powers Noetik’s pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications.

"Noetik’s multiple spatial AI models, including the Oncology Counterfactual Therapeutics Oracle virtual cell, which can simulate patient biology and inform drug discovery, represent transformative breakthroughs for tackling human disease," said Dr. Mark R. Munch, President of the Bruker NANO Group. To develop self-supervised AI, Noetik leverages the CosMx SMI platform to generate the largest and most biologically complete single-cell and subcellular spatial transcriptomic and multiomic datasets in oncology.

Noetik is now further imaging thousands of additional patients with the CosMx whole transcriptome assay to train their world models that learn from human tissue data.

"Spatial context is necessary for training foundation models that truly learn human biology. We have demonstrated that our models exhibit clear scaling laws; as we ingest more high-resolution CosMx data, we see a predictable and powerful increase in the models’ ability to represent complex biology. We are excited to partner with Bruker to scale toward one billion spatially resolved human cells, spanning the breadth of oncology and beyond," said Ron Alfa, MD, PhD, Co-Founder and CEO of Noetik.

This collaboration builds on Bruker’s best-in-class spatial biology portfolio, including CosMx SMI, AtoMx SIP, CellScape XR, GeoMx DSP and PaintScape platform, which together support high fidelity data generation for discovery and translational research.

(Press release, Noetik AI, FEB 24, 2026, View Source [SID1234662954])

AdvanCell Showcases Novel TheraPb Phase 2 Study Design of ADVC001 for the Treatment of Metastatic Prostate Cancer at ASCO GU Symposium 2026

On February 24, 2026 AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, reported the novel Phase 2 design of the ongoing TheraPb clinical trial of ADVC001 in metastatic prostate cancer. ADVC001 is an investigational Lead-212-based prostate-specific membrane antigen (PSMA)-targeted alpha therapy. The study design will be showcased in a ‘Trials in Progress’ poster this week at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Genitourinary Cancers Symposium (ASCO GU 2026) in San Francisco, CA.

The TheraPb Phase 2 is an open-label, randomized expansion study incorporating dose optimization strategies in three groups of patients with metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). The study’s innovative design is supported by the Phase 1b dose escalation results, which showed encouraging safety and promising anti-tumor activity of ADVC001. At the recommended Phase 2 dose, 80% of patients achieved a 50% reduction in prostate-specific antigen (PSA50), and a 100% overall response rate was observed in patients with evaluable tumors, while no dose-limiting toxicities and no toxicity-related treatment discontinuations or dose modifications were observed. ADVC001 exhibited rapid and high tumor uptake, fast renal clearance, and low normal-organ radiation exposure.

"The Phase 2 TheraPb trial employs a novel dosing strategy that incorporates more frequent up-front treatment leveraging the half-life of Lead-212, as well as taking into account patient-specific responses," commented Thomas Hope, MD, Vice Chair Clinical Operations and Strategy, Department of Radiology and Biomedical Imaging, University of California San Francisco. "This approach is the first in the next generation of radioligand therapy trials that goes beyond standard dosing strategies in order to improve patient outcomes."

"ADVC001 is a promising alpha PSMA-directed theranostic treatment that uses an innovative payload of Lead-212." commented Michael J. Morris, MD, Prostate Cancer Section Head, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center. "The study examines the merits of a treatment intensification strategy, adaptive dosing, and application across multiple clinical settings under the auspices of a novel study design intended to facilitate efficient development."

"The TheraPb Phase 2 incorporates dose optimization strategies designed to improve patient outcomes in three distinct prostate cancer populations across the disease continuum, with high unmet medical need." said Anna Karmann, MD PhD, Chief Medical Officer at AdvanCell. "To maximize clinical benefit and minimize toxicity, we are investigating novel dosing regimens aiming to optimize timing and duration of treatment. Encouraged by the favorable safety and tolerability results of ADVC001 in Phase 1b, the study also includes evaluation of extended treatment in participants who demonstrate ongoing benefit."

The TheraPb Phase 2 expansion is designed to optimize ADVC001 development opportunities. Participants with mHSPC (suboptimal responders), mCRPC (pre-chemotherapy) and mCRPC (post-177Lu-PSMA) are randomized to either 160 or 200 MBq of ADVC001 and receive up to 4 doses of ADVC001 during a dose-intense induction. Additional doses may be administered as maintenance treatment for a total of up to 12 doses, allowing for a treatment pause (‘treatment holiday’) based on individual response.

The TheraPb Phase 2 trial (NCT05720130) is open at clinical sites in Australia, with planned expansion to additional sites in the United States.

Trials in Progress Poster at ASCO (Free ASCO Whitepaper) GU 2026

Presentation Title: Phase 2 Expansion Study of 212Pb-ADVC001 in Metastatic Prostate Cancer: The TheraPb Trial
Presenter: Professor Aaron Hansen, Princess Alexandra Hospital, Brisbane, Australia
Abstract Number: TPS280, Board N16
Session: Trials in Progress Poster Session A: Prostate Cancer
Date and Time: 26-February – 11:30 AM – 12:45 PM and 5:45 PM – 6:45 PM Pacific Time
The presentation will be available on AdvanCell’s website at www.advancell.com.au/presentations-publications.

About 212Pb-ADVC001

212Pb-ADVC001 (ADVC001) is a proprietary and patented PSMA-targeting radioligand with optimized physicochemical properties and labelled with Lead-212 (212Pb), an alpha-emitting payload (radionuclide) with a high dose rate, 10.6-hour half-life and simple decay scheme. ADVC001 is designed to deliver radiation at a cellular level to effectively kill prostate cancer cells while minimizing toxicity.

About the TheraPb trial

The TheraPb trial (NCT05720130) is a prospective, open-label Phase 1/2 dose escalation and expansion study evaluating ADVC001 in metastatic prostate cancer. The completed Phase 1b dose escalation assessed the safety and tolerability of escalating doses of ADVC001 administered every 6, 4, 2 or 1 week(s) (see press release). The Phase 2 expansion is assessing the efficacy and safety of ADVC001 at two dose levels. The trial utilizes a randomized dose-response design and dose optimization elements to evaluate ADVC001 in PSMA-positive mCRPC and in mHSPC.

(Press release, Advancell, FEB 24, 2026, View Source [SID1234662953])